← Browse by Condition
Medical Condition

carcinoma hepatocellular

Total Trials
4
Recruiting Now
4
Trial Phases
Phase 1, Phase 2

ClinicalMetric tracks all active clinical trials for carcinoma hepatocellular sourced from ClinicalTrials.gov. Research in this area spans early-phase safety investigations through large Phase 3 confirmatory trials, conducted by NIH-funded academic centers, independent investigators, and pharmaceutical sponsors worldwide. Each listing is updated daily as new studies open enrollment and existing ones reach capacity or complete follow-up.

Trial listings include the NCT identifier, current recruitment status, phase classification, primary and secondary endpoints, estimated enrollment size, participating countries, and direct links to the full protocol on ClinicalTrials.gov. Eligibility criteria — including age range, disease stage, and prior treatment requirements — are documented for every study to help patients and clinicians assess suitability before contacting a trial site.

Frequently Asked Questions — carcinoma hepatocellular Clinical Trials

How many clinical trials are currently recruiting for carcinoma hepatocellular?
ClinicalMetric currently tracks 4 actively recruiting clinical trials for carcinoma hepatocellular, sourced in real time from ClinicalTrials.gov. The total number of registered studies—including those not yet enrolling or in active follow-up—is 4. Trial availability changes daily as new studies open enrollment and existing ones reach capacity.
What trial phases are available for carcinoma hepatocellular?
carcinoma hepatocellular research spans Phase 1 (2 trials), Phase 2 (2 trials). Phase 1 studies evaluate safety and dosing in small groups, Phase 2 studies assess preliminary efficacy in 100–300 participants, and Phase 3 trials compare the new treatment against the standard of care in 300–3,000+ patients. Phase 4 post-approval studies monitor long-term outcomes in real-world populations.
How do I find out if I qualify for a carcinoma hepatocellular clinical trial?
Eligibility criteria for carcinoma hepatocellular trials vary by study and typically specify age range, disease stage or severity, prior treatment history, and specific diagnostic or laboratory parameters. Each listing on ClinicalMetric links to the full protocol on ClinicalTrials.gov, where inclusion and exclusion criteria are documented. Contact the sponsoring site's research coordinator directly to confirm your eligibility—your treating physician or specialist can also help identify the most appropriate trial based on your medical history and current treatment status.
Trial Phases
Phase 1
2
Phase 2
2
Top Sponsors
Qilu Hospital of Shandong University 1 trial
Abivax S.A. 1 trial
Pfizer 1 trial
VA Office of Research and Development 1 trial

Recruiting Clinical Trials

NCT06571396
Recruiting
Perioperative Risk of Immunotherapy Based Neoadjuvant and Conversion Therapy for Hepatocellular Carcinoma
Enrollment
200 pts
Location
China
Sponsor
Qilu Hospital of Shandong Univ...
View Trial →
NCT03897543 Phase 1, Phase 2
Recruiting
ABX196 in Combination With Nivolumab in Patients With Hepatocellular Carcinoma
Enrollment
48 pts
Location
United States
Sponsor
Abivax S.A.
View Trial →
NCT07227012 Phase 1, Phase 2
Recruiting
Symbiotic-GI-13: A Study to Learn About Study Medicine Called PF-08634404 as a Single Treatment and Combination Treatment in Adult Participants With a Liver Cancer Called Hepatocellular Carcinoma, That is Too Advanced to be Removed by Surgery and May Have Spread to Other Parts of the Body.
Enrollment
138 pts
Location
United States, Japan...
Sponsor
Pfizer
View Trial →
NCT05486572
Recruiting
Preventing Liver Cancer Mortality Through Imaging With Ultrasound vs. MRI
Enrollment
4,700 pts
Location
United States
Sponsor
VA Office of Research and Deve...
View Trial →

Related Conditions

immunotherapy (1) hepatocellular cancer (1) hepatocellular carcinoma (1) unresectable hepatocellular carcinoma (1) liver neoplasms (1) advanced hepatocellular carcinoma (1) metastatic hepatocellular carcinoma (1) cirrhosis (1)
ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology